Fig. 3: Pharmacokinetic properties of rentosertib. | Nature Medicine

Fig. 3: Pharmacokinetic properties of rentosertib.

From: A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial

Fig. 3

a–c, Pharmacokinetic dynamics of rentosertib in patient sera collected predose and periodically throughout 24 h posttreatment at week 0 (a), at 0 h posttreatment at weeks 2, 4 and 8 (b) and 48 h after administration at week 12 (c). d, AUC0–t of rentosertib exposure; n = 22 in 30 mg QD, n = 21 in 30 mg BID, n = 20 in 60 mg QD. e, Cmax of rentosertib exposure; n = 22 in 30 mg QD, n = 21 in 30 mg BID, n = 20 in 60 mg QD. f, Ctrough of rentosertib exposure in patient sera collected pretreatment at weeks 0, 2, 4, 8 and 12. All data represent arithmetic mean ± s.d.

Back to article page